Mathias Loft - Search Results

Year	Number of Results
2016	2
2017	2
2018	1
2019	1
2020	2
2021	5
2022	7
2023	3
2024	0

1

Editorial for "Quantification of Prostate Cancer Metabolism Using 3D Multiecho bSSFP and Hyperpolarized [1-¹³ C] Pyruvate: Metabolism Differs Between Tumors of the Same Gleason Grade".

Clemmensen A, Loft M, Kjaer A, Andersen TL. Clemmensen A, et al. Among authors: loft m. J Magn Reson Imaging. 2023 Jun;57(6):1876-1877. doi: 10.1002/jmri.28483. Epub 2022 Nov 3. J Magn Reson Imaging. 2023. PMID: 36326566 No abstract available.

2

[⁶⁸Ga]Ga-NODAGA-E[(cRGDyK)]₂ Angiogenesis PET/MR in a Porcine Model of Chronic Myocardial Infarction.

Bentsen S, Clemmensen A, Loft M, Flethøj M, Debes KP, Ludvigsen TP, Larsen CB, Kirchhoff J, Olsen LH, Møller JE, Andersen TL, Johannesen HH, Jespersen T, Kjaer A. Bentsen S, et al. Among authors: loft m. Diagnostics (Basel). 2021 Sep 30;11(10):1807. doi: 10.3390/diagnostics11101807. Diagnostics (Basel). 2021. PMID: 34679505 Free PMC article.

3

Prospective Phase II Trial of [⁶⁸Ga]Ga-NODAGA-E[c(RGDyK)]₂ PET/CT Imaging of Integrin α_vβ₃ for Prognostication in Patients with Neuroendocrine Neoplasms.

Carlsen EA, Loft M, Loft A, Czyzewska D, Andreassen M, Langer SW, Knigge U, Kjaer A. Carlsen EA, et al. Among authors: loft m. J Nucl Med. 2023 Feb;64(2):252-259. doi: 10.2967/jnumed.122.264383. Epub 2022 Aug 18. J Nucl Med. 2023. PMID: 35981899 Free PMC article. Clinical Trial.

4

A convolutional neural network for total tumor segmentation in [⁶⁴Cu]Cu-DOTATATE PET/CT of patients with neuroendocrine neoplasms.

Carlsen EA, Lindholm K, Hindsholm A, Gæde M, Ladefoged CN, Loft M, Johnbeck CB, Langer SW, Oturai P, Knigge U, Kjaer A, Andersen FL. Carlsen EA, et al. Among authors: loft m. EJNMMI Res. 2022 May 28;12(1):30. doi: 10.1186/s13550-022-00901-2. EJNMMI Res. 2022. PMID: 35633448 Free PMC article.

5

Activity Dose Reduction in ⁶⁴Cu-DOTATATE PET in Patients with Neuroendocrine Neoplasms: Impact on Image Quality and Lesion Detection Ability.

Loft M, Carlsen EA, Johnbeck CB, Jensen CV, Andersen FL, Langer SW, Oturai P, Knigge U, Kjaer A. Loft M, et al. Mol Imaging Biol. 2022 Aug;24(4):600-611. doi: 10.1007/s11307-022-01706-4. Epub 2022 Feb 15. Mol Imaging Biol. 2022. PMID: 35167028

6

Prospective Phase II Trial of Prognostication by ⁶⁸Ga-NOTA-AE105 uPAR PET in Patients with Neuroendocrine Neoplasms: Implications for uPAR-Targeted Therapy.

Carlsen EA, Loft M, Loft A, Berthelsen AK, Langer SW, Knigge U, Kjaer A. Carlsen EA, et al. Among authors: loft m. J Nucl Med. 2022 Sep;63(9):1371-1377. doi: 10.2967/jnumed.121.263177. Epub 2022 Jan 20. J Nucl Med. 2022. PMID: 35058319 Free PMC article. Clinical Trial.

7

A Randomized, Factorial Phase II Study to Determine the Optimal Dosing Regimen for ⁶⁸Ga-Satoreotide Trizoxetan as an Imaging Agent in Patients with Gastroenteropancreatic Neuroendocrine Tumors.

Virgolini I, Bahri S, Kjaer A, Grønbæk H, Iversen P, Carlsen EA, Loft M, Knigge U, Maffey-Steffan J, Powell C, Miller CG, Rohban T, McEwan S, Czernin J. Virgolini I, et al. Among authors: loft m. J Nucl Med. 2022 Mar;63(3):376-383. doi: 10.2967/jnumed.121.261936. Epub 2021 Jul 2. J Nucl Med. 2022. PMID: 34215673 Free PMC article. Clinical Trial.

8

First-in-Humans PET Imaging of Tissue Factor in Patients with Primary and Metastatic Cancers Using ¹⁸F-labeled Active-Site Inhibited Factor VII (¹⁸F-ASIS): Potential as Companion Diagnostic.

Loft M, Christensen C, Clausen MM, Carlsen EA, Hansen CP, Kroman N, Langer SW, Høgdall C, Madsen J, Gillings N, Nielsen CH, Klausen TL, Holm S, Loft A, Berthelsen AK, Kjaer A. Loft M, et al. J Nucl Med. 2022 Dec;63(12):1871-1879. doi: 10.2967/jnumed.122.264068. Epub 2022 May 19. J Nucl Med. 2022. PMID: 35589407 Free PMC article. Clinical Trial.

9

An Investigation of Lesion Detection Accuracy for Artificial Intelligence-Based Denoising of Low-Dose ⁶⁴Cu-DOTATATE PET Imaging in Patients with Neuroendocrine Neoplasms.

Loft M, Ladefoged CN, Johnbeck CB, Carlsen EA, Oturai P, Langer SW, Knigge U, Andersen FL, Kjaer A. Loft M, et al. J Nucl Med. 2023 Jun;64(6):951-959. doi: 10.2967/jnumed.122.264826. Epub 2023 May 11. J Nucl Med. 2023. PMID: 37169532 Free PMC article.

10

⁶⁴Cu-DOTATATE PET/CT and Prediction of Overall and Progression-Free Survival in Patients with Neuroendocrine Neoplasms.

Carlsen EA, Johnbeck CB, Binderup T, Loft M, Pfeifer A, Mortensen J, Oturai P, Loft A, Berthelsen AK, Langer SW, Knigge U, Kjaer A. Carlsen EA, et al. Among authors: loft m. J Nucl Med. 2020 Oct;61(10):1491-1497. doi: 10.2967/jnumed.119.240143. Epub 2020 Feb 28. J Nucl Med. 2020. PMID: 32111685 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

18 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Results by year